fbpx

BioTech startup Synthace gets £7.3m Series A

BioTech firm Synthace has raised £7.3m in Series A funding from investors including White Cloud Capital, Amadeus Capital Partners and Eleven Two Capital.

Existing shareholders Sofinnova Partners, SOSV and Bioeconony Capital also participated.

The company, which has created proprietary language and software platform Antha specifically for biologists, says it will use the cash to gain further traction and expand in the market.

Antha, the company says, is designed to make reproducible and scalable workflows that can be readily edited and shared, and easily automated on labs’ existing equipment.

Synthace CEO Tim Fell said: “Our need to heal, feed, fuel and manufacture for a growing population can be met by unlocking the near infinite power of biology but only by bringing software abstraction and more automation to biological R&D and manufacturing, and by enabling biologists to build atop their collective work. That is what the Antha platform does, and why we are so passionate about realizing its potential.”

Isabel Fox, head of venture at White Cloud Capital, spoke about her firm’s decision to back the London-based firm: “Synthace is transforming the way biotechnology is developed and the $170bn global life science R&D budget spent.

“The traction the Company has achieved with pharmaceutical, agritech and industrial biotechnology customers shows the cross-sector applicability of Antha. We are excited to support the company in bringing this technology to the immense market of any researcher or organisation developing products or services that incorporate biology.”

Hermann Hauser, co-founder and partner, Amadeus Capital Partners, added:“Biotechnology has mass application, a true general purpose technology. Its development is challenging and Synthace is empowering biotechnologists to better understand and work with its complex nature.

“Amadeus is delighted to join this outstanding team on their important journey. Bioengineering and its implications for the future depend upon achieving step-change improvements in reproducibility, productivity and cost, all of which the Antha platform can deliver.”

Check out our UK tech investment tracker for the latest industry deals.